Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a) (Lp(a), levels at or over 150 nmol/L and stable atherosclerotic
William Blair initiated coverage on Eyenovia Inc (NASDAQ: EYEN), a biopharma company focused on developing therapies based on its Optejet device, which leverages a microdose array print (MAP) technology that allows consistent, reproducible dosing of ophthalmic drugs.
TG Therapeutics Inc (NASDAQ: TGTX) reported Q3 FY23 Briumvi sales of $25.1 million compared to $16 million in Q2 FY23 in the U.S., with total net product revenue of approximately